文献速递浆细胞疾病

复发/难治性多发性骨髓瘤中伊沙佐米联合来那度胺/地塞米松相关不良事件的管理

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
PubMed 文献 · Br J Haematol · 2017-05-09

口服蛋白酶体抑制剂伊沙佐米联合口服来那度胺和地塞米松(Rd)已在美国、欧盟等获批用于既往接受过至少一线治疗的多发性骨髓瘤患者。获批基于全球随机双盲安慰剂对照III期TOURMALINE-MM1研究,伊沙佐米-Rd(IRd)较安慰剂-Rd显著改善无进展生存期(中位20.6 vs 14.7个月;风险比0.74)。本文综述该研究安全性数据,并提供IRd相关临床不良事件的管理指导。

要点

  • IRd较安慰剂-Rd更常见的毒性包括血小板减少、恶心、呕吐、腹泻、便秘、皮疹、周围神经病、外周水肿和背痛,除血小板减少(3/4级19% vs 9%)外多为1/2级。
  • 血小板减少看起来可控且可逆,两组在显著出血或因不良事件停药方面无差异。
  • 未观察到累积毒性,提示长期IRd治疗具有潜在可行性;多数毒性可通过支持治疗及按需剂量延迟或减量管理。

核心结论

  • IRd较安慰剂-Rd显著改善复发/难治性多发性骨髓瘤患者的无进展生存期(中位20.6 vs 14.7个月;风险比0.74)。
  • IRd相关常见毒性多数为1/2级,血小板减少看起来可控且可逆,未观察到累积毒性,提示长期治疗具有潜在可行性。
  • 临床医生应认识并理解这些潜在副作用,以优化并延长患者获益。

研究设计与样本

  • 全球、随机、双盲、安慰剂对照III期TOURMALINE-MM1研究,比较伊沙佐米联合来那度胺和地塞米松(IRd)与安慰剂-Rd在复发/难治性多发性骨髓瘤患者中的疗效与安全性。
  • 口服蛋白酶体抑制剂伊沙佐米已在美国、欧盟和其他国家获批,与口服来那度胺和地塞米松(Rd)联合用于既往接受过至少一线治疗的多发性骨髓瘤患者。

主要发现

  • IRd较安慰剂-Rd显著改善无进展生存期:中位20.6 vs 14.7个月;风险比0.74。
  • IRd较安慰剂-Rd更常见的毒性包括血小板减少、恶心、呕吐、腹泻、便秘、皮疹、周围神经病、外周水肿和背痛;除血小板减少外,这些毒性一般为1/2级。
  • 血小板减少3/4级发生率IRd组19% vs 安慰剂-Rd组9%,看起来可控且可逆。
  • 两组在显著出血或因不良事件停药方面无差异。
  • 未观察到累积毒性,提示长期IRd治疗具有潜在可行性。

临床怎么用

  • 多数毒性可通过支持治疗以及按需剂量延迟或减量进行管理。
  • 临床医生应认识并理解IRd的潜在副作用,以优化并延长患者获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double-blind, placebo-controlled Phase III TOURMALINE-MM1 study of ixazomib-Rd (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression-free survival versus placebo-Rd (median: 20·6 vs. 14·7 months; hazard ratio 0·74). Common toxicities observed more commonly with IRd versus placebo-Rd were thrombocytopenia, nausea, vomiting, diarrhoea, constipation, rash, peripheral neuropathy, peripheral oedema and back pain; these were generally grade 1/2 in severity except for thrombocytopenia (19% vs. 9% grade 3/4), which appeared manageable and reversible, with no differences between arms in significant bleeding or dose discontinuations. No cumulative toxicities were observed, indicating the potential feasibility of long-term IRd treatment. Safety data from TOURMALINE-MM1 are reviewed and guidance for managing clinically relevant adverse events associated with IRd is provided. Most toxicities were manageable with supportive care and dose delays or reductions as needed. Clinicians should be aware of and understand these potential side effects to optimise and prolong patient benefit.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017. PMID: 28485007. doi:10.1111/bjh.14733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。